Compare Boston Scientific Corporation (BSX) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs NEOS S&P 500 High Income ETF — how do they compare? Boston Scientific Corporation trades at $43.38 (market cap $66.37B), while NEOS S&P 500 High Income ETF trades at $53.68. The key difference: NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | SPYI | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $108.14 | $54.07 |
52-Week Low | $42.63 | $47.98 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
SPYI trades at $53.37, down 0.61% on the day, with a bullish technical signal supported by moving averages. The NEOS S&P 500 High Income ETF has surpassed $10 billion in assets under management, driven by strong investor demand for its monthly income strategy. Recent dividend payments of $0.52-$0.54 demonstrate consistent distribution capabilities, while technical indicators show support at $53 and resistance at $54.
The ETF's covered-call strategy provides high monthly income with partial upside participation, making it attractive for income-focused investors. However, the 0.68% expense ratio and potential return of capital distributions present cost considerations. Market volatility benefits the options strategy, though competition with JEPI and other income ETFs remains a key factor.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
